-
Health-related quality of life, work ability and disability among individuals with persistent post-dural puncture headache J. Headache Pain (IF 7.4) Pub Date : 2024-04-24 Ali Kapan, Thomas Waldhör, Tobias Schiffler, Jürgen Beck, Christian Wöber
Postdural puncture headache (PDPH) is an acknowledged consequence of procedures like lumbar punctures, epidural analgesia, and neurosurgical interventions. Persistence over more than three months, however has been poorly studied. In particular, little is known about the impact of persistent PDPH (pPDPH) on health related quality of life (HRQoL), disability and ability to work. The study aimed to provide
-
Female-selective mechanisms promoting migraine J. Headache Pain (IF 7.4) Pub Date : 2024-04-24 Shagun Singh, Caroline M. Kopruszinski, Moe Watanabe, David W. Dodick, Edita Navratilova, Frank Porreca
Sexual dimorphism has been revealed for many neurological disorders including chronic pain. Prelicinal studies and post-mortem analyses from male and female human donors reveal sexual dimorphism of nociceptors at transcript, protein and functional levels suggesting different mechanisms that may promote pain in men and women. Migraine is a common female-prevalent neurological disorder that is characterized
-
Trends and prescribing patterns of antimigraine medicines in nine major cities in China from 2018 to 2022: a retrospective prescription analysis J. Headache Pain (IF 7.4) Pub Date : 2024-04-23 Jing Huang, Xinwei Wang, Yiyi Jin, Guodong Lou, Zhenwei Yu
The objective of this study was to investigate the trends and prescribing patterns of antimigraine medicines in China. The prescription data of outpatients diagnosed with migraine between 2018 and 2022 were extracted from the Hospital Prescription Analysis Cooperative Project of China. The demographic characteristics of migraine patients, prescription trends, and corresponding expenditures on antimigraine
-
Unsatisfactory response to acute medications does not affect the medication overuse headache development in pediatric chronic migraine J. Headache Pain (IF 7.4) Pub Date : 2024-04-23 Ilaria Frattale, Michela Ada Noris Ferilli, Fabiana Ursitti, Giorgia Sforza, Gabriele Monte, Martina Proietti Checchi, Samuela Tarantino, Luigi Mazzone, Massimiliano Valeriani, Laura Papetti
Chronic migraine (CM) negatively impacts the quality of life of 2 to 4% of pediatric patients. In adults, CM is frequently linked to medication overuse headache (MOH), but there is a much lower prevalence of MOH in children. A suboptimal response to acute therapies may lead to their reduced use, thus preventing MOH development in children and adolescents. The frequency of patients with CM who do not
-
Healthcare utilisation and economic burden of migraines among bank employees in China: a probabilistic modelling study J. Headache Pain (IF 7.4) Pub Date : 2024-04-19 Du Wei, Li Ping Wong, Xun He, Tharani Loganathan
Despite the recognised high prevalence of migraines among bank employees, yet their healthcare utilisation patterns and the economic burden of migraines remain underexplored. To examine migraine-related healthcare utilisation among bank employees in China, and to estimate the economic burden of migraines. A cross-sectional survey was conducted in Guizhou province, China between May and October 2022
-
An economic evaluation of eptinezumab for the preventive treatment of migraine in the UK, with consideration for natural history and work productivity J. Headache Pain (IF 7.4) Pub Date : 2024-04-18 Edward Griffin, Gawain Shirley, Xin Ying Lee, Susanne F. Awad, Alok Tyagi, Peter J. Goadsby
Migraine is a highly prevalent neurological disease with a substantial societal burden due to lost productivity. From a societal perspective, we assessed the cost-effectiveness of eptinezumab for the preventive treatment of migraine. An individual patient simulation of discrete competing events was developed to evaluate eptinezumab cost-effectiveness compared to best supportive care for adults in the
-
Dynamic fluctuations of salivary CGRP levels during migraine attacks: association with clinical variables and phenotypic characterization J. Headache Pain (IF 7.4) Pub Date : 2024-04-18 Alicia Alpuente, Victor J. Gallardo, Laila Asskour, Edoardo Caronna, Marta Torres-Ferrus, Patricia Pozo-Rosich
Migraine is a complex neurological disorder with significant heterogeneity in its clinical presentation and molecular mechanisms. Calcitonin gene-related peptide (CGRP) has emerged as a key player in migraine pathophysiology, but challenges remain in its utilization as a biomarker. This study aimed to investigate salivary CGRP levels during migraine attacks across the frequency spectrum and explore
-
Effects of PDE-3 inhibition in persistent post-traumatic headache: evidence of cAMP-dependent signaling J. Headache Pain (IF 7.4) Pub Date : 2024-04-17 Haidar M. Al-Khazali, Rune H. Christensen, Basit Ali Chaudhry, Anna G. Melchior, Messoud Ashina, Rami Burstein, Håkan Ashina
Phosphodiesterase 3 (PDE-3) inhibition have been implicated in the neurobiologic underpinnings of migraine. Considering the clinical similarities between migraine and persistent post-traumatic headache (PPTH), we aimed to ascertain whether PDE-3 inhibition can elicit migraine-like headache in persons with PPTH. We tested cilostazol, which inhibits PDE-3, in a randomized, double-blind, placebo-controlled
-
Rimegepant orally disintegrating tablet 75 mg for acute treatment of migraine in adults from China: a subgroup analysis of a double-blind, randomized, placebo-controlled, phase 3 clinical trial J. Headache Pain (IF 7.4) Pub Date : 2024-04-16 Shengyuan Yu, Aihong Guo, Zhen Wang, Jianguang Liu, Ge Tan, Qian Yang, Mingjie Zhang, Hasiyeti Yibulaiyin, Huisheng Chen, Yongbo Zhang, Robert Croop, Yanhui Sun, Yu Liu, Qian Zhao, Zhihong Lu
Rimegepant orally disintegrating tablet (ODT), an oral small-molecule calcitonin gene-related peptide receptor antagonist, is indicated for acute and preventive treatment of migraine in the United States and other countries. Previously, a large clinical trial assessed the efficacy and safety of rimegepant ODT 75 mg for the acute treatment of migraine in adults living in China or South Korea. A post
-
Photophobia is associated with lower sleep quality in individuals with migraine: results from the American Registry for Migraine Research (ARMR) J. Headache Pain (IF 7.4) Pub Date : 2024-04-12 Nina Sharp, Mark J Burish, Kathleen B Digre, Jessica Ailani, Mahya Fani, Sophia Lamp, Todd J. Schwedt
Patients with migraine often have poor sleep quality between and during migraine attacks. Furthermore, extensive research has identified photophobia as the most common and most bothersome symptom in individuals with migraine, second only to headache. Seeking the comfort of darkness is a common strategy for managing pain during an attack and preventing its recurrence between episodes. Given the well-established
-
Reconceptualizing autonomic function testing in migraine: a systematic review and meta-analysis J. Headache Pain (IF 7.4) Pub Date : 2024-04-10 Antun R. Pavelić, Karin Zebenholzer, Christian Wöber
Autonomic nervous system (ANS) testing has aided in our ability to evaluate autonomic dysfunction in migraine patients. We reviewed the literature in multiple databases which investigate ANS function in migraine patients and healthy subjects. This systematic review and meta-analysis examined the respective deep breathing, Valsalva manoeuvre, orthostatic and isometric challenge results, using the Preferred
-
Alterations of the alpha rhythm in visual snow syndrome: a case-control study J. Headache Pain (IF 7.4) Pub Date : 2024-04-08 Antonia Klein, Sarah A. Aeschlimann, Frederic Zubler, Adrian Scutelnic, Franz Riederer, Matthias Ertl, Christoph J. Schankin
Visual snow syndrome is a disorder characterized by the combination of typical perceptual disturbances. The clinical picture suggests an impairment of visual filtering mechanisms and might involve primary and secondary visual brain areas, as well as higher-order attentional networks. On the level of cortical oscillations, the alpha rhythm is a prominent EEG pattern that is involved in the prioritisation
-
The prevalence and demographic associations of headache in the adult population of Benin: a cross-sectional population-based study J. Headache Pain (IF 7.4) Pub Date : 2024-04-05 Thierry Adoukonou, Mendinatou Agbetou, Eric Dettin, Oyene Kossi, Andreas Husøy, Hallie Thomas, Dismand Houinato, Timothy J Steiner
The Global Burden of Disease (GBD) study is increasingly well informed with regard to headache disorders, but sub-Saharan Africa (SSA) remains one of the large regions of the world with limited data directly derived from population-based studies. The Global Campaign against Headache has conducted three studies in this region: Ethiopia in the east, Zambia in the south and Cameroon in Central SSA. Here
-
CGRP-targeted medication in chronic migraine - systematic review J. Headache Pain (IF 7.4) Pub Date : 2024-04-05 Renato Oliveira, Raquel Gil-Gouveia, Francesca Puledda
Chronic migraine is a highly debilitating condition that is often difficult to manage, particularly in the presence of medication overuse headache. Drugs targeting the calcitonin gene-related peptide (CGRP), or its receptor have shown promising results in treating this disorder. We searched Pubmed and Embase to identify randomized clinical trials and real-world studies reporting on the use of medication
-
The prevalence of headache in the adult population of Morocco: a cross-sectional population-based study J. Headache Pain (IF 7.4) Pub Date : 2024-04-03 Najib Kissani, Latifa Adarmouch, Aboubacar Sidik Sidibe, Abderrahmane Garmane, Rachid Founoun, Mohamed Chraa, Hallie Thomas, Andreas Husøy, Timothy J Steiner
The series of population-based studies conducted by the Global Campaign against Headache has, so far, included Pakistan and Saudi Arabia from the Eastern Mediterranean Region. The Maghreb countries of North Africa, also part of this Region, are geographically apart and culturally very different from these countries. Here we report a study in Morocco. We applied the standardised methodology of Global
-
The prevalence and demographic associations of headache in the adult population of Peru: a national cross-sectional population-based study J. Headache Pain (IF 7.4) Pub Date : 2024-04-03 Guiovanna Quispe, Cesar Loza, Luis Limaco, Ruth Gallegos, Carlos Palomino, Ivett Cruz, Jacqueline Miranda, Liliana Rodriguez, Andreas Husøy, Timothy J Steiner
The Global Campaign against Headache is conducting a series of population-based studies to fill the large geographical gaps in knowledge of headache prevalence and attributable burden. One major region not until now included is South America. Here we present a study from Peru, a country of 32.4 million inhabitants located at the west coast of South America, notable for its high Andes mountains. The
-
Unveiling the therapeutic potential of Dl-3-n-butylphthalide in NTG-induced migraine mouse: activating the Nrf2 pathway to alleviate oxidative stress and neuroinflammation J. Headache Pain (IF 7.4) Pub Date : 2024-04-02 Yingyuan Liu, Zihua Gong, Deqi Zhai, Chunxiao Yang, Guangshuang Lu, Shuqing Wang, Shaobo Xiao, Chenhao Li, Ludan Chen, Xiaoxue Lin, Shuhua Zhang, Shengyuan Yu, Zhao Dong
Migraine stands as a prevalent primary headache disorder, with prior research highlighting the significant involvement of oxidative stress and inflammatory pathways in its pathogenesis and chronicity. Existing evidence indicates the capacity of Dl-3-n-butylphthalide (NBP) to mitigate oxidative stress and inflammation, thereby conferring neuroprotective benefits in many central nervous system diseases
-
The burden attributable to primary headache disorders in children and adolescents in Ethiopia: estimates from a national schools-based study J. Headache Pain (IF 7.4) Pub Date : 2024-04-02 Yared Zenebe Zewde, Mehila Zebenigus, Hanna Demissie, Redda Tekle-Haimanot, Derya Uluduz, Tayyar Şaşmaz, Fatma Bozdag, Timothy J Steiner
We previously reported high prevalences of headache disorders among children (6–11 years) and adolescents (12–17 years) in Ethiopia. Here we provide data on headache-attributed burden collected contemporaneously from the same study participants. Part of the global schools-based programme within the Global Campaign against Headache, the study is the first to present such data from sub-Saharan Africa
-
Increased CX3CL1 in cerebrospinal fluid and ictal serum t-tau elevations in migraine: results from a cross-sectional exploratory case-control study J. Headache Pain (IF 7.4) Pub Date : 2024-04-02 Marie Süße, Christine Kloetzer, Sebastian Strauß, Johanna Ruhnau, Lucas Hendrik Overeem, Merle Bendig, Juliane Schulze, Uwe Reuter, Antje Vogelgesang, Robert Fleischmann
To date, migraine is diagnosed exclusively based on clinical criteria, but fluid biomarkers are desirable to gain insight into pathophysiological processes and inform clinical management. We investigated the state-dependent profile of fluid biomarkers for neuroaxonal damage and microglial activation as two potentially relevant aspects in human migraine pathophysiology. This exploratory study included
-
Structural equation modeling for identifying the drivers of health-related quality of life improvement experienced by patients with migraine receiving eptinezumab J. Headache Pain (IF 7.4) Pub Date : 2024-03-28 Linus Jönsson, Susanne F. Awad, Stephane A. Regnier, Brian Talon, Steven Kymes, Xin Ying Lee, Peter J. Goadsby
As new migraine therapies emerge, it is crucial for measures to capture the complexities of health-related quality of life (HRQoL) improvement beyond improvements in monthly migraine day (MMD) reduction. Investigations into the correlations between MMD reduction, symptom management, and HRQoL are lacking, particularly those that focus on improvements in canonical symptoms and improvement in patient-identified
-
Frequency and predictors of headache in the first 12 months after traumatic brain injury: results from CENTER-TBI J. Headache Pain (IF 7.4) Pub Date : 2024-03-25 Emilie Isager Howe, Nada Andelic, Cathrine Brunborg, Marina Zeldovich, Eirik Helseth, Toril Skandsen, Alexander Olsen, Silje C. R. Fure, Alice Theadom, Katrin Rauen, Benedikte Å. Madsen, Bram Jacobs, Joukje van der Naalt, Maria Carmela Tartaglia, Cathrine Elisabeth Einarsen, Gøril Storvig, Erling Tronvik, Cathrine Tverdal, Nicole von Steinbüchel, Cecilie Røe, Torgeir Hellstrøm
Headache is a prevalent and debilitating symptom following traumatic brain injury (TBI). Large-scale, prospective cohort studies are needed to establish long-term headache prevalence and associated factors after TBI. This study aimed to assess the frequency and severity of headache after TBI and determine whether sociodemographic factors, injury severity characteristics, and pre- and post-injury comorbidities
-
Long-term treatment with lasmiditan in patients with migraine: post hoc analysis of treatment patterns and outcomes from the open-label extension of the CENTURION randomized trial J. Headache Pain (IF 7.4) Pub Date : 2024-03-25 Mika Komori, Akichika Ozeki, Yuka Tanji, Eriko Kamiki, John H. Krege, Lily Qian Li, Shiho Suzuki, Mamoru Shibata, Takao Takeshima
The objective of this analysis was to gain new insights into the patient characteristics and other factors associated with lasmiditan usage and clinical outcomes under conditions resembling the real-world setting. This was a post hoc analysis of data from the 12-month, open-label extension (OLE) of the phase 3, double-blind, randomized, controlled CENTURION trial, which examined the efficacy and safety
-
Headache in the adult population of Cameroon: prevalence estimates and demographic associations from a cross-sectional nationwide population-based study J. Headache Pain (IF 7.4) Pub Date : 2024-03-21 Callixte Kuate Tegueu, Anastase Dzudie Tamdja, Franklin Kom, Blaise Forgwa Barche, Peter Ebasone, Mélanie Magnerou, Paul Mbonda, Jacques Doumbe, Andreas Husøy, Hallie Thomas, Timothy J. Steiner
Knowledge of headache prevalence, and the burdens attributable to headache disorders, remains incomplete in sub-Saharan Africa (SSA): reliable studies have been conducted only in Zambia (southern SSA) and Ethiopia (eastern SSA). As part of the Global Campaign against Headache, we investigated the prevalence of headache in Cameroon, in Central SSA. We used the same methodology as the studies in Zambia
-
The burden of headache disorders in North India: methodology, and validation of a Hindi version of the HARDSHIP questionnaire, for a community-based survey in Delhi and national capital territory region J. Headache Pain (IF 7.4) Pub Date : 2024-03-19 Ashish Duggal, Debashish Chowdhury, Anand Krishnan, Ritvik Amarchand, Timothy J. Steiner
Knowledge of the prevalence and attributable burden of headache disorders in India is sparse, with only two recent population-based studies from South and East India. These produced conflicting results. A study in North India is needed. We report the methodology of such a study using, and validating, a Hindi translation of the Headache-Attributed Restriction, Disability, Social Handicap, and Impaired
-
Is erenumab an efficient alternative for the prevention of episodic and chronic migraine in Spain? Results of a cost-effectiveness analysis J. Headache Pain (IF 7.4) Pub Date : 2024-03-15 Patricia Pozo-Rosich, José Luis Poveda, Carlos Crespo, María Martínez, José Manuel Rodríguez, Pablo Irimia
The reimbursement of erenumab in Spain and other European countries is currently restricted because of the cost of this novel therapy to patients with migraine who have experienced previous failures to traditional preventive treatments. However, this reimbursement policy should be preferably based on cost-effectiveness studies, among other criteria. This study performed a cost-effectiveness analysis
-
CGRP-monoclonal antibodies in Japan: insights from an online survey of physician members of the Japanese headache society J. Headache Pain (IF 7.4) Pub Date : 2024-03-15 Tsubasa Takizawa, Keiko Ihara, Narumi Watanabe, Ryo Takemura, Nobuyuki Takahashi, Naoki Miyazaki, Mamoru Shibata, Keisuke Suzuki, Noboru Imai, Norihiro Suzuki, Koichi Hirata, Takao Takeshima, Jin Nakahara
Anti-calcitonin gene-related peptide monoclonal antibodies (CGRPmAbs) have greatly changed migraine treatment options. In Japan, although CGRPmAb guidelines (≥ 4 monthly migraine days (MMDs) and ≥ 1 previous preventive failure) are well-acknowledged, the actual use of CGRPmAbs and the circumstances of the related headache care are unknown. We conducted an online survey of Japanese Headache Society
-
Societal and economic burden of migraine in Spain: results from the 2020 National Health and Wellness Survey J. Headache Pain (IF 7.4) Pub Date : 2024-03-15 David García-Azorín, Carlota Moya-Alarcón, Beatriz Armada, Margarita Sánchez del Río
The burden of migraine goes beyond the pain and associated symptoms. We aimed to describe the impact of migraine in healthcare resource utilization (HCRU), work productivity, and mood disorders, as well as its economic cost. Case–control study nested in a cross-sectional analysis of patient-reported data collected between 30/12/2019 and 20/04/2020 as part of the National Health and Wellness Survey
-
Specific cognitive and psychological alterations are more strongly linked to increased migraine disability than chronic migraine diagnosis J. Headache Pain (IF 7.4) Pub Date : 2024-03-15 Tatiana Castro Zamparella, Mariela Carpinella, Mario Peres, Florencia Patricia Cuello, Pilar Maza, Melanie Van Gansen, Marcelo Filipchuk, Verónica Balaszczuk, Carolina Maldonado, Pablo Scarnato, Diego Conci Magris, Marco Lisicki
The efficiency of The International Classification of Headache Disorders (ICHD-3) in reflecting patients’ disability has recently been questioned. This prompts consideration that clinical features beyond pain may more accurately indicate the extent of underlying brain impairment than the mere frequency of headache days. Important cognitive dysfunctions and psychological impairment have been reported
-
Calcitonin receptor, calcitonin gene-related peptide and amylin distribution in C1/2 dorsal root ganglia J. Headache Pain (IF 7.4) Pub Date : 2024-03-14 Tayla A. Rees, Zoe Tasma, Michael L. Garelja, Simon J. O’Carroll, Christopher S. Walker, Debbie L. Hay
The upper cervical dorsal root ganglia (DRG) are important for the transmission of sensory information associated with the back of the head and neck, contributing to head pain. Calcitonin receptor (CTR)-based receptors, such as the amylin 1 (AMY1) receptor, and ligands, calcitonin gene-related peptide (CGRP) and amylin, have been linked to migraine and pain. However, the contribution of this system
-
Safety and tolerability of atogepant for the preventive treatment of migraine: a post hoc analysis of pooled data from four clinical trials J. Headache Pain (IF 7.4) Pub Date : 2024-03-11 Paul Rizzoli, Michael J. Marmura, Jennifer Robblee, Jennifer McVige, Sara Sacco, Stephanie J. Nahas, Jessica Ailani, Rosa De Abreu Ferreira, Julia Ma, Jonathan H. Smith, Brett Dabruzzo, Messoud Ashina
Conventional, non-specific preventive migraine treatments often demonstrate low rates of treatment persistence due to poor efficacy or tolerability. Effective, well-tolerated preventive treatments are needed to reduce migraine symptoms, improve function, and enhance quality of life. Atogepant is a migraine-specific oral calcitonin gene–related peptide receptor antagonist that is indicated for the preventive
-
The glymphatic system in migraine and other headaches J. Headache Pain (IF 7.4) Pub Date : 2024-03-11 Maria Grazia Vittorini, Aysenur Sahin, Antonin Trojan, Sevil Yusifli, Tamta Alashvili, Gonçalo V. Bonifácio, Ketevan Paposhvili, Viktoria Tischler, Christian Lampl, Simona Sacco
Glymphatic system is an emerging pathway of removing metabolic waste products and toxic solutes from the brain tissue. It is made of a network of perivascular spaces, filled in cerebrospinal and interstitial fluid, encompassing penetrating and pial vessels and communicating with the subarachnoid space. It is separated from vessels by the blood brain barrier and from brain tissue by the endfeet of the
-
Decoding pain through facial expressions: a study of patients with migraine J. Headache Pain (IF 7.4) Pub Date : 2024-03-11 Wei-Ta Chen, Fu-Jung Hsiao, Gianluca Coppola, Shuu-Jiun Wang
The present study used the Facial Action Coding System (FACS) to analyse changes in facial activities in individuals with migraine during resting conditions to determine the potential of facial expressions to convey information about pain during headache episodes. Facial activity was recorded in calm and resting conditions by using a camera for both healthy controls (HC) and patients with episodic
-
AMPK activation attenuates central sensitization in a recurrent nitroglycerin-induced chronic migraine mouse model by promoting microglial M2-type polarization J. Headache Pain (IF 7.4) Pub Date : 2024-03-08 Guangshuang Lu, Shaobo Xiao, Fanchao Meng, Leyi Zhang, Yan Chang, Jinjing Zhao, Nan Gao, Wenjie Su, Xinghao Guo, Yingyuan Liu, Chenhao Li, Wenjing Tang, Liping Zou, Shengyuan Yu, Ruozhuo Liu
Energy metabolism disorders and neurogenic inflammation play important roles in the central sensitization to chronic migraine (CM). AMP-activated protein kinase (AMPK) is an intracellular energy sensor, and its activation regulates inflammation and reduces neuropathic pain. However, studies on the involvement of AMPK in the regulation of CM are currently lacking. Therefore, this study aimed to explore
-
Commentary on 2022 guidelines on clinical trial design in cluster headache and further suggestions J. Headache Pain (IF 7.4) Pub Date : 2024-03-07 Ioana Medrea, Stewart J. Tepper, Donliang Wang, Paul G. Mathew, Mark Burish
New guidelines for cluster headache clinical trials were recently published. We welcome these new guidelines and raise additional considerations in trial methodologies. We present non-inferiority trials to overcome ethical issues with placebo use, and additionally discuss issues with trial recruitment. We highlight some possible issues and solutions to be considered with the recently published cluster
-
One-year prevalence of cluster headache, hemicrania continua, paroxysmal hemicrania and SUNCT in Norway: a population-based nationwide registry study J. Headache Pain (IF 7.4) Pub Date : 2024-03-06 Knut Hagen
There is lack of population-based studies evaluating the prevalence of paroxysmal hemicrania, hemicrania continua and short-lasting unilateral neuralgiform headache attacks. The aim of this study was to investigate the gender-specific 1-year prevalence of cluster headache, paroxysmal hemicrania, hemicrania continua, and short-lasting unilateral neuralgiform headache attacks. A nationwide study was
-
The crucial role of locus coeruleus noradrenergic neurons in the interaction between acute sleep disturbance and headache J. Headache Pain (IF 7.4) Pub Date : 2024-03-05 Bozhi Li, Ya Cao, Huijuan Yuan, Zhe Yu, Shuai Miao, Chunxiao Yang, Zihua Gong, Wei Xie, Chenhao Li, Wenhao Bai, Wenjing Tang, Dengfa Zhao, Shengyuan Yu
Both epidemiological and clinical studies have indicated that headache and sleep disturbances share a complex relationship. Although headache and sleep share common neurophysiological and anatomical foundations, the mechanism underlying their interaction remains poorly understood. The structures of the diencephalon and brainstem, particularly the locus coeruleus (LC), are the primary sites where the
-
LncRNA Anxa10-203 enhances Mc1r mRNA stability to promote neuropathic pain by recruiting DHX30 in the trigeminal ganglion J. Headache Pain (IF 7.4) Pub Date : 2024-03-04 YaJing Liu, Fei Liu, YiKe Li, YueLing Li, YuHeng Feng, JiaShuo Zhao, Cheng Zhou, ChunJie Li, JieFei Shen, YanYan Zhang
Trigeminal nerve injury is one of the most serious complications in oral clinics, and the subsequent chronic orofacial pain is a consumptive disease. Increasing evidence demonstrates long non-coding RNAs (lncRNAs) play an important role in the pathological process of neuropathic pain. This study aims to explore the function and mechanism of LncRNA Anxa10-203 in the development of orofacial neuropathic
-
The impact of primary headaches on disability outcomes: a literature review and meta-analysis to inform future iterations of the Global Burden of Disease study J. Headache Pain (IF 7.4) Pub Date : 2024-03-04 Marta Waliszewska-Prosół, Danilo Antonio Montisano, Mariola Antolak, Federico Bighiani, Francescantonio Cammarota, Ilaria Cetta, Michele Corrado, Keiko Ihara, Regina Kartamysheva, Igor Petrušić, Maria Magdalena Pocora, Tsubasa Takizawa, Gloria Vaghi, Paolo Martelletti, Barbara Corso, Alberto Raggi
The burden and disability associated with headaches are conceptualized and measured differently at patients’ and populations’ levels. At the patients’ level, through patient-reported outcome measures (PROMs); at population level, through disability weights (DW) and years lived with a disability (YLDs) developed by the Global Burden of Disease Study (GBD). DW are 0–1 coefficients that address health
-
Harris Poll Migraine Report Card: population-based examination of high-frequency headache/migraine and acute medication overuse J. Headache Pain (IF 7.4) Pub Date : 2024-02-26 Amaal J. Starling, Roger Cady, Dawn C. Buse, Meghan Buzby, Charlie Spinale, Kathy Steinberg, Kevin Lenaburg, Steven Kymes
Migraine is a disabling neurologic disease that can fluctuate over time in severity, frequency, and acute medication use. Harris Poll Migraine Report Card was a US population-based survey to ascertain quantifiable distinctions amongst individuals with current versus previous high-frequency headache/migraine and acute medication overuse (HFM+AMO). The objective of this report is to compare self-reported
-
Postdromal symptoms in migraine: a REFORM study J. Headache Pain (IF 7.4) Pub Date : 2024-02-21 Janu Thuraiaiyah, Håkan Ashina, Rune Häckert Christensen, Haidar M. Al-Khazali, Messoud Ashina
Migraine is a multiphasic neurovascular disorder, where headache can be succeeded by postdromal symptoms. However, there are limited research on postdromal symptoms. This study aimed to investigate the proportion of individuals with migraine from a tertiary care unit reporting postdromal symptoms in adherence with the ICHD-3 definition. We also aimed to examine how the means of enquiry might influence
-
Associations of combined lifestyle index with migraine prevalence and headache frequency: a cross-sectional study from the MECH-HK study J. Headache Pain (IF 7.4) Pub Date : 2024-02-20 Yunyang Deng, Harry Haoxiang Wang, Fei Wan Ngai, Dexing Zhang, Jing Qin, Xiangyan Chen, Yao Jie Xie
Prior research has shown that individual lifestyles were associated with migraine. Yet, few studies focused on combined lifestyles, particularly in Chinese populations. This cross-sectional study aimed to investigate the relationships of a combined lifestyle index with migraine in Hong Kong Chinese women. Baseline data from a cohort study named Migraine Exposures and Cardiovascular Health in Hong Kong
-
Lipopolysaccharide, VE-cadherin, HMGB1, and HIF-1α levels are elevated in the systemic circulation in chronic migraine patients with medication overuse headache: evidence of leaky gut and inflammation J. Headache Pain (IF 7.4) Pub Date : 2024-02-19 Doga Vuralli, Merve Ceren Akgor, Hale Gok Dagidir, Ozlem Gulbahar, Meltem Yalinay, Hayrunnisa Bolay
Medication overuse headache (MOH) was recently shown to be associated with leaky gut in rodents. We aimed to investigate whether chronic migraine (CM) patients with MOH have elevated lipopolysaccharide levels and inflammatory molecules in blood circulation. The study included women participants (40 CM patients with NSAID overuse headache, 35 episodic migraine (EM) patients, and 20 healthy non-headache
-
Clinical features of migraine with aura: a REFORM study J. Headache Pain (IF 7.4) Pub Date : 2024-02-13 Andreas Vinther Thomsen, Håkan Ashina, Haidar M. Al-Khazali, Kathrine Rose, Rune Häckert Christensen, Faisal Mohammad Amin, Messoud Ashina
About one-third of persons with migraine experience transient neurologic symptoms, referred to as aura. Despite its widespread prevalence, comprehensive clinical descriptions of migraine with aura remain sparse. Therefore, we aimed to provide an in-depth phenotypic analysis of aura symptoms and characteristics in a cross-sectional study of a large sample of adults diagnosed with migraine with aura
-
Influence of metabolic state and body composition on the action of pharmacological treatment of migraine J. Headache Pain (IF 7.4) Pub Date : 2024-02-13 Noor Bruijn, Romy van Lohuizen, Malgorzata Boron, Mira Fitzek, Francesca Gabriele, Giada Giuliani, Laura Melgarejo, Pavel Řehulka, Gabriele Sebastianelli, Paul Triller, Simone Vigneri, Behiye Özcan, Antoinette Maassen van den Brink
Migraine is a disabling neurovascular disorder among people of all ages, with the highest prevalence in the fertile years, and in women. Migraine impacts the quality of life of affected individuals tremendously and, in addition, it is associated with highly prevalent metabolic diseases, such as obesity, diabetes mellitus and thyroid dysfunction. Also, the clinical response to drugs might be affected
-
Early and annual projected savings from anti-CGRP monoclonal antibodies in migraine prevention: a cost-benefit analysis in the working-age population J. Headache Pain (IF 7.4) Pub Date : 2024-02-12 Carlos Lazaro-Hernandez, Edoardo Caronna, Joana Rosell-Mirmi, Victor J Gallardo, Alicia Alpuente, Marta Torres-Ferrus, Patricia Pozo-Rosich
Migraine is one of the main causes of disability worldwide. Anti-CGRP monoclonal antibodies (MAbs) have proven to be safe and efficacious as preventive migraine treatments. However, their use is restricted in many countries due to their apparently high cost. Cost-benefit studies are needed. To study the cost-benefit of anti-CGRP MAbs in working-age patients with migraine. This is a prospective cohort
-
Treatment patterns and characteristics of patients with migraine: results from a retrospective database study in Japan J. Headache Pain (IF 7.4) Pub Date : 2024-02-08 Tsubasa Takizawa, Takahiro Kitano, Masahiro Iijima, Kanae Togo, Naohiro Yonemoto
Clinical characteristics and treatment practice of patients with migraine in Japan in real-world setting have not been fully investigated. We conducted a retrospective cohort study using claims database to understand the clinical practice of migraine in recent years and to characterize patients potentially not managed well by current treatment options. Our study used data from the large claims database
-
Factors associated to the presence of headache in patients with influenza infection and its consequences: a 2010–2020 surveillance-based study J. Headache Pain (IF 7.4) Pub Date : 2024-02-08 David García-Azorín, Laura Santana-López, José Eugenio Lozano-Alonso, Ana Ordax-Díez, Tomas Vega-Alonso, Diego Macias Saint-Gerons, Yésica González-Osorio, Silvia Rojo-Rello, José M. Eiros, Javier Sánchez-Martínez, Álvaro Sierra-Mencía, Andrea Recio-García, Alejandro Martín-Toribio, Ivan Sanz-Muñoz, Ángel Luis Guerrero-Peral
Headache is a common symptom of influenza infection; however, its causes and consequences remain uncertain. In this manuscript, we analyzed which demographic and clinical factors were associated with the presence of headache during the course of influenza infection and whether patients with headache had a different prognosis, evaluated by need of hospitalization, sick leave or school absenteeism. The
-
Dynamic changes in glymphatic function in reversible cerebral vasoconstriction syndrome J. Headache Pain (IF 7.4) Pub Date : 2024-02-05 Chia-Hung Wu, Yu Kuo, Yu-Hsiang Ling, Yen-Feng Wang, Jong-Ling Fuh, Jiing-Feng Lirng, Hsiu-Mei Wu, Shuu-Jiun Wang, Shih-Pin Chen
The pathophysiology of the reversible cerebral vasoconstriction syndrome (RCVS) remains enigmatic and the role of glymphatics in RCVS pathophysiology has not been evaluated. We aimed to investigate RCVS glymphatic dynamics and its clinical correlates. We prospectively evaluated the glymphatic function in RCVS patients, with RCVS subjects and healthy controls (HCs) recruited between August 2020 and
-
Comparison of effectiveness and safety of lasmiditan and CGRP-antagonists for the acute treatment of migraine in adults: systematic review and network meta-analysis of randomised trials J. Headache Pain (IF 7.4) Pub Date : 2024-02-05 Xinxin Deng, Liying Zhou, Cui Liang, Xue Shang, Xu Hui, Wendi Liu, Shanshan Liang, Yongsheng Wang, Meng Xu, Kangle Guo, Kehu Yang, Xiuxia Li
To compare the outcomes associated with the use of lasmiditan, rimegepant, ubrogepant, and zavegepant for the acute management of migraine headaches. We searched four electronic databases from database inception to August 31, 2023, to identify randomized controlled trials (RCTs) that report efficacy and safety for the acute treatment of migraine. The risk of bias in the included RCTs was evaluated
-
Validity and reliability of Arabic version of pediatric migraine disability assessment scale (Child Self-Report versus Parent Proxy-Report): a multi-center study J. Headache Pain (IF 7.4) Pub Date : 2024-02-05 Rehab Magdy, Amr Hassan, Zeinab Mohammed, Mohamed A. Abdeltwab, Nawal F. Abdel Ghaffar, Mona Hussein
Pediatric Migraine Disability Assessment (PedMIDAS) is one of the most frequently used questionnaires to assess disability from migraine in pediatric patients. This work aimed to evaluate the validity and test–retest reliability of the Arabic version of the child self-report versus the parent proxy report PedMIDAS. We also aimed to test the agreement between children's and parents' reports of the scale
-
Arterial hypertension in the chronic evolution of migraine: bystander or risk factor? An overview J. Headache Pain (IF 7.4) Pub Date : 2024-02-05 Federico Mazzacane, Gloria Vaghi, Matteo Cotta Ramusino, Giulia Perini, Alfredo Costa
Several risk factors are associated with the chronic evolution of migraine. Clinical and preclinical studies have provided data about the role of hypertension (HT) as one of the potential modifiable risk factors of chronic migraine (CM). This review is focused on the biological and clinical evidence supporting common mechanisms underlying HT and migraine and the potential role of HT in the transition
-
Real-world effectiveness of Anti-CGRP monoclonal antibodies compared to OnabotulinumtoxinA (RAMO) in chronic migraine: a retrospective, observational, multicenter, cohort study J. Headache Pain (IF 7.4) Pub Date : 2024-02-02 Licia Grazzi, Riccardo Giossi, Danilo Antonio Montisano, Mattia Canella, Marilena Marcosano, Claudia Altamura, Fabrizio Vernieri
Chronic migraine (CM) is a disabling condition with high prevalence in the general population. Until the recent approval of monoclonal antibodies targeting the calcitonin gene-related peptide (Anti-CGRP mAbs), OnabotulinumtoxinA (BoNT-A) was the only treatment specifically approved for CM prophylaxis. Direct comparisons between the two treatments are not available so far. We performed an observational
-
Health equity, care access and quality in headache – part 1 J. Headache Pain (IF 7.4) Pub Date : 2024-01-29 Claudio Tana, Bianca Raffaelli, Marcio Nattan Portes Souza, Elena Ruiz de la Torre, Daniel Gams Massi, Najib Kisani, David García-Azorín, Marta Waliszewska-Prosół
Current definitions of migraine that are based mainly on clinical characteristics do not account for other patient’s features such as those related to an impaired quality of life, due to loss of social life and productivity, and the differences related to the geographical distribution of the disease and cultural misconceptions which tend to underestimate migraine as a psychosocial rather than neurobiological
-
Migraine - a borderland disease to epilepsy: near it but not of it J. Headache Pain (IF 7.4) Pub Date : 2024-01-26 Jakob Paungarttner, Martina Quartana, Lucrezia Patti, Barbora Sklenárová, Fatemeh Farham, Inés Hernando Jiménez, M. Gokcen Soylu, Irina Maria Vlad, Semih Tasdelen, Teresa Mateu, Oreste Marsico, Federica Reina, Viktoria Tischler, Christian Lampl
Migraine and epilepsy are two paroxysmal chronic neurological disorders affecting a high number of individuals and being responsible for a high individual and socioeconomic burden. The link between these disorders has been of interest for decades and innovations concerning diagnosing and treatment enable new insights into their relationship. Although appearing to be distinct at first glance, both diseases
-
Calcitonin gene-related peptide antagonists in pregnancy: a disproportionality analysis in VigiBase® J. Headache Pain (IF 7.4) Pub Date : 2024-01-19 Roberta Noseda, Francesca Bedussi, Claudio Gobbi, Alessandro Ceschi, Chiara Zecca
Current evidence on the safety of calcitonin gene–related peptide antagonists (CGRP-A) in pregnancy for the treatment of both episodic and chronic migraine is scarce and does not yet provide definitive information. By querying VigiBase®, the World Health Organization global pharmacovigilance database, this study aimed to detect differences in the reporting frequency between CGRP-A and triptans in relation
-
Anti-CGRP antibody galcanezumab modifies the function of the trigeminovascular nocisensor complex in the rat J. Headache Pain (IF 7.4) Pub Date : 2024-01-19 Nadine Friedrich, Krisztina Németh, Martin Tanner, Judit Rosta, Ildikó Dobos, Orsolya Oszlács, Gábor Jancsó, Karl Messlinger, Mária Dux
Monoclonal antibodies directed against the neuropeptide calcitonin gene-related peptide (CGRP) are effective in the prevention of chronic and frequent episodic migraine. Since the antibodies do not cross the blood brain barrier, their antinociceptive effect is attributed to effects in meningeal tissues. We aimed to probe if such an antibody can be visualized within the dura mater and the trigeminal
-
Different vulnerability of fast and slow cortical oscillations to suppressive effect of spreading depolarization: state-dependent features potentially relevant to pathogenesis of migraine aura J. Headache Pain (IF 7.4) Pub Date : 2024-01-15 Tatiana M. Medvedeva, Maria P. Smirnova, Irina V. Pavlova, Lyudmila V. Vinogradova
Spreading depolarization (SD), underlying mechanism of migraine aura and potential activator of pain pathways, is known to elicit transient local silencing cortical activity. Sweeping across the cortex, the electrocorticographic depression is supposed to underlie spreading negative symptoms of migraine aura. Main information about the suppressive effect of SD on cortical oscillations was obtained in
-
Mechanosensitive receptors in migraine: a systematic review J. Headache Pain (IF 7.4) Pub Date : 2024-01-15 Adriana Della Pietra, Laura Gómez Dabó, Petr Mikulenka, Christian Espinoza-Vinces, Doga Vuralli, Isil Baytekin, Paolo Martelletti, Rashid Giniatullin
Migraine is a debilitating neurological disorder with pain profile, suggesting exaggerated mechanosensation. Mechanosensitive receptors of different families, which specifically respond to various mechanical stimuli, have gathered increasing attention due to their potential role in migraine related nociception. Understanding these mechanisms is of principal importance for improved therapeutic strategies
-
Involvement of the ipsilateral-to-the-pain anterior–superior hypothalamic subunit in chronic cluster headache J. Headache Pain (IF 7.4) Pub Date : 2024-01-11 Stefania Ferraro, Anna Nigri, Maria Grazia Bruzzone, Jean Paul Medina Carrion, Davide Fedeli, Greta Demichelis, Luisa Chiapparini, Giuseppe Ciullo, Ariosky Areces Gonzalez, Alberto Proietti Cecchini, Luca Giani, Benjamin Becker, Massimo Leone
Despite hypothalamus has long being considered to be involved in the pathophysiology of cluster headache, the inconsistencies of previous neuroimaging studies and a limited understanding of the hypothalamic areas involved, impede a comprehensive interpretation of its involvement in this condition. We used an automated algorithm to extract hypothalamic subunit volumes from 105 cluster headache patients
-
Double-blind, randomized, placebo-controlled study to evaluate erenumab-specific central effects: an fMRI study J. Headache Pain (IF 7.4) Pub Date : 2024-01-09 Hauke Basedau, Kuan-Po Peng, Marlene Schellong, Arne May
Given the findings of central effects of erenumab in the literature, we aimed to conduct a rigorous placebo-controlled, double-blind, randomized study to elucidate whether the observed changes are directly attributable to the drug. We recruited 44 patients with migraine, randomly assigning them to either the erenumab 70 mg or the placebo group. 40 patients underwent fMRI scanning using a trigeminal